Overcoming Endocrine Resistance in Hormone Receptor Positive Breast Cancer

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 218 papers19 conceptsfrozen 2026-10-04

The primary challenge in treating hormone receptor-positive (HR+) breast cancer is not the initial response, but the eventual failure of endocrine therapy. While drugs like tamoxifen or aromatase inhibitors effectively block estrogen signaling, approximately one-third of patients develop resistance, leading to metastatic recurrence. Research has shifted from simply blocking the estrogen receptor (ER) to identifying the bypass mechanisms—genomic, epigenetic, and metabolic—that allow cancer cells to survive and proliferate without hormonal cues.

The Mechanisms of Escape

Resistance often arises when cancer cells "rewire" their survival pathways to bypass the need for estrogen. This can occur through the activation of alternative growth signals or the physical alteration of the estrogen receptor itself.

  • Receptor Degradation and Modification: Instead of merely blocking the ER, new strategies focus on destroying it. LSZ102 is an oral selective estrogen receptor degrader (SERD) designed to eliminate the protein entirely. Other researchers, such as Wěi Li, have shown that proteins like c-Cbl can disrupt membrane complexes (ER-c-Src-HER2) that drive resistance in HER2-overexpressing cases.
  • Cell Cycle Hijacking: Even when estrogen is blocked, tumors can force cell division by activating cyclin-dependent kinases. The development of CDK4/6 inhibitors, chronicled by Richard S. Finn and Hope S. Rugo, has become a cornerstone of treatment. Newer agents like bireociclib, studied by Jiayu Wang, and SHR6390 aim to restore cell cycle control in patients who have failed prior lines of therapy.
  • Kinase Signaling Pathways: Resistance is frequently driven by the PI3K/AKT pathway. Xichun Hu demonstrated that adding the AKT inhibitor capivasertib to fulvestrant can double progression-free survival. Similarly, Koichi Ito identified PTK6 as a survival regulator that, when inhibited, unleashes cell death pathways in resistant cells.

Epigenetic and Metabolic Drivers

Beyond direct signaling, the cellular state and environment play critical roles in how a tumor responds to treatment.

  • Stem-like Properties: Xue Lin and Jian Li found that tamoxifen resistance is linked to an epigenetic shift toward a "stem-like" state, driven by the upregulation of the pluripotency factor SOX2. This suggests that resistance is a programmed survival state rather than just a collection of random mutations.
  • Metabolic Reprogramming: Tumors also adapt their metabolism to support rapid growth. Yue Yu identified RBP7 as a tumor suppressor that normally restricts the fatty acids cancer cells need; its loss allows the AKT/SREBP1 pathway to fuel resistant growth.
  • RNA-Level Regulation: Novel mechanisms like "miRancers" (RNA motifs that stabilize microRNAs), described by Gaopeng Li, and stealth fusion transcripts like RAD51AP1-DYRK4, identified by Chia-Chia Liu, provide new precision targets for tumors that no longer respond to hormone-based drugs.

Predicting and Personalizing Response

Understanding why resistance happens allows for better patient stratification. Giampaolo Bianchini and Lajos Pusztai showed that high proliferation rates and low hormone receptor activity can distinguish patients at risk for early versus late relapse. Furthermore, the ICARUS-BREAST01 trial suggests that a tumor's spatial architecture and the absence of specific mutations (like ESR1) are more predictive of success for new antibody-drug conjugates than simple protein expression levels.

Papers in this version

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 24 papers
  2. Version 1 · 2026-10-04 · 18 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_endocrine_therapy_resistance_5e781ff9,
  title = {endocrine therapy resistance},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/endocrine-therapy-resistance/rdr_5e781ff935a84eb1b7f0c18b1ada476b},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 1, frozen text):

@misc{lacuna_overcoming_endocrine_resistance_in_hormo_5e781ff9_v1,
  title = {Overcoming Endocrine Resistance in Hormone Receptor Positive Breast Cancer},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/overcoming-endocrine-resistance-in-hormone-receptor-positive-breast-cancer/rdr_5e781ff935a84eb1b7f0c18b1ada476b/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-22},
}